Stay updated on APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe page adds a government funding notice banner and updates the revision from v3.4.0 to v3.4.1, which affects only site-wide notices and versioning rather than core trial data; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check13 days agoChange DetectedThe history page now includes a glossary, color-coded change highlights (green for additions, red for deletions), and a visible revision label (v3.4.0). This is a UI/readability improvement that does not affect core study data.SummaryDifference0.6%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe screenshot shows a minor version update from Revision: v3.3.3 to v3.3.4 in the Record History; no substantive changes to trial data or page content are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedAdded a new revision entry: Revision: v3.3.3 to the history. Removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the history.SummaryDifference0.1%

- Check76 days agoChange DetectedThe history adds a Terminated status and indicates Results Posted with new Outcome Measures (Results). A new Revision: v3.3.2 entry dated 2025-11-21 is recorded.SummaryDifference0.6%

- Check84 days agoChange DetectedRemoved the government funding lapse notice that was previously displayed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APX005M + Pembrolizumab in Metastatic Melanoma Clinical Trial page.